Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH

PURPOSE: Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including endocrinopathy. Hypophysitis is one of the most common endocrine abnormalities. An...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, M. S., Lai, Z. M., Spain, L., Greener, V., Turajlic, S., Larkin, J., Morganstein, D. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796881/
https://www.ncbi.nlm.nih.gov/pubmed/32449093
http://dx.doi.org/10.1007/s40618-020-01297-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796881/
https://www.ncbi.nlm.nih.gov/pubmed/32449093
http://dx.doi.org/10.1007/s40618-020-01297-3

Ejemplares similares